SLU-PP-332

Research ChemicalPreliminary Research

Also known as: ERR Agonist · Exercise Mimetic

A novel ERR (estrogen-related receptor) agonist that mimics the molecular effects of exercise, enhancing endurance, fat oxidation, and muscle fiber type switching.

Overview

SLU-PP-332 is a small molecule agonist of estrogen-related receptors (ERRs) — a family of orphan nuclear receptors that are key regulators of energy metabolism and mitochondrial function. ERRs are naturally activated by exercise and play a central role in the adaptive response to endurance training, including mitochondrial biogenesis, fatty acid oxidation, and the switch from fast-twitch (glycolytic) to slow-twitch (oxidative) muscle fibers. In preclinical research published in 2023, SLU-PP-332 demonstrated remarkable exercise-mimetic effects: treated mice showed significantly enhanced running endurance, increased oxidative muscle fiber content, improved fat metabolism, and resistance to diet-induced obesity — all without actual exercise. This compound represents a new class of exercise mimetics distinct from AICAR and Cardarine, targeting a different molecular pathway.

Mechanism of Action

Activates estrogen-related receptors (ERRalpha, ERRbeta, ERRgamma), which translocate to the nucleus and upregulate genes involved in oxidative phosphorylation, fatty acid oxidation, mitochondrial biogenesis, and muscle fiber type specification. Promotes the conversion of type IIb (fast glycolytic) to type IIa/I (slow oxidative) muscle fibers.

Key Benefits

Enhanced endurance capacity
Increased fat oxidation
Muscle fiber type optimization
Mitochondrial biogenesis
Resistance to diet-induced obesity
Novel exercise-mimetic mechanism

Potential Side Effects

Limited human safety data
Potential hormonal interactions (ERR pathway)
Injection site reactions
GI discomfort (oral)

Common Stacks

This peptide is commonly combined with the following compounds for synergistic effects:

AICARCardarine (GW-501516)L-CarnitineITPP

Known Interactions

The following interactions have been documented for SLU-PP-332. Always consult a healthcare professional before combining compounds.

Synergistic (1)

Cardarine (PPARδ agonist) and SLU-PP-332 (ERRα/γ agonist) both enhance endurance through complementary nuclear receptor pathways. Powerful exercise mimetic stack.

View all compound interactions

Scientific References

Quick Reference

Typical Dose

500mcg-1500mcg

Frequency

2-3x daily AM/Mid/PM

Route

Subcutaneous injection or oral

Half-Life

~4-8 hours

Cycle Length

8-16 weeks; daily use, followed by 4 weeks recovery

FDA Status

Research compound — not FDA approved. Preclinical data only (published 2023).

Need to calculate dosing?

Use our reconstitution calculator to determine exact syringe measurements.

Open Calculator

This information is for educational purposes only. Consult a qualified healthcare professional before using any peptide. Dosing information reflects commonly reported protocols and may not be appropriate for everyone.

Related Peptides in Performance & Body Composition